|
|
 |
Afferent Pharmaceuticals Announces Data
Supporting Potential Utility of Proprietary P2X3 Antagonists in Regulating
Bladder Reflexes
August 25, 2010
Oxford Immunotec announces US FDA
approval of PMA supplement for the use of the T-Cell Xtend® reagent
August 11, 2010
WorldHeart Receives FDA Approval to Add
Clinical Sites in Levacor™ VAD Bridge-to-Transplant Study
July 27, 2010
Epocrates, Inc. Files Registration Statement
for Proposed Initial Public Offering
July 16, 2010
Presidio Pharmaceuticals, Inc. Successfully
Completes Phase 1a Clinical Trial of PPI-461, a Potent, New Hepatitis C Virus
(HCV) Inhibitor
July 14, 2010
Synageva Biopharma Receives Orphan Drug Designation for SBC-102 for Lysosomal
Acid Lipase Deficiency
July 7, 2010
ISTA Pharmaceuticals Announces Phase
III Results For Once-Daily Topical Xibrom™ 0.09%
July 1, 2010
Tolerx Initiates Confirmatory Phase 3
Clinical Trial, DEFEND-2, with Otelixizumab for Type 1 Diabetes
June 28, 2010
Tolerx Presents Baseline Data from DEFEND-1
Study Validating C-Peptide as Critical Clinical Measure for New-Onset Type 1
Diabetes
June 28, 2010
Olympus to Acquire Spiration, Inc., a
U.S. Pulmonary Device Company, as a Consolidated Subsidiary
June 25, 2010
Tioga Pharmaceuticals Begins Phase 3 Trial of
Asimadoline in Irritable Bowel Syndrome
June 3, 2010
Sandoz completes acquisition of Oriel
Therapeutics, strengthening potential for global leadership in respiratory
June 3, 2010
Presidio Pharmaceuticals, Inc. Selects Second
Clinical Candidate from Hepatitis C Virus NS5A Inhibitor Program
May 26, 2010
Spiration Announces Positive Results of
European Study Evaluating Safety and Effectiveness of Bronchial Valve Treatment
for Severe Emphysema
May 19, 2010
Altura Medical Completes $20 Million
Round of Financing
May 18, 2010
Pearl Therapeutics’ Data for its Combination
Bronchodilator Product, PT003, Support the Potential for Improvement in the
Treatment of Patients with COPD
May 18, 2010
Nycomed and Forest Laboratories receive
complete FDA response letter for Roflumilast – no additional patient trials were
requested
May 17, 2010
Prometheus Unveils Novel Approach for
Predicting Risk of Disease Progression in Patients with Crohn’s Disease
May 3, 2010
Oxford Immunotec Closes Second Tranche of $26
Million Series D Financing Led by New Leaf Venture Partners
April 30, 2010
GE Healthcare and Nycomed to Form Joint Venture to Sell, Market and Distribute Medical Diagnostic Contrast Agents in Russia and CIS
April 27, 2010
VaxInnate’s VAX125 Seasonal Flu Vaccine
Shown Safe and Highly Immunogenic in Phase II Study of Elderly Subjects
April 27, 2010
Presidio Pharmaceuticals, Inc.
Initiates First-in-Human Clinical Trial of PPI-461, an Investigational NS5A
Inhibitor for HCV
April 27, 2010
Nycomed and Merck & Co., Inc.,
Announce Commercialization Agreements for Daxas® in Europe and Canada
April 26, 2010
Nycomed’s Novel Anti-Inflammatory Therapy
Daxas® (Roflumilast) Recommended for Approval in the European Union for Patients
with COPD
April 23, 2010
Sandoz to acquire Oriel Therapeutics, gaining
rights to portfolio of respiratory products targeting asthma and COPD
April 19, 2010
WorldHeart Announces Levacor VAD Implant at
Inova Fairfax Hospital, Virginia
April 13, 2010
NxStage® Expands Streamline® Blood Tubing Set
and MasterGuard® Needle Supply Agreement with Renal Advantage Inc.
April 12, 2010
Nycomed and Baxter receive FDA approval for
TachoSil®, an adjunct to haemostasis in cardiovascular surgery
April 6, 2010
Tioga Pharmaceuticals Receives Special
Protocol Assessment Agreement from FDA for Phase 3 Trials of Asimadoline in
Irritable Bowel Syndrome
April 5, 2010
Concert Pharmaceuticals Granted Patent for
Deuterated Paroxetine Compounds, Including CTP-347
March 31 , 2010
Interlace Medical Initiates Clinical Trial of
Myosuretm for Office-Based Treatment of Submucosal Fibroids
March 30, 2010
Pearl Therapeutics Announces Positive Results From Phase 1 Trial of Pt003, a Bronchodilator Combination Therapeutic for Chronic Obstructive Pulmonary Disease, and Initiation of Phase 2b Trial
March 29, 2010
Transcept Pharmaceuticals Updates Plan for Intermezzo® NDA Resubmission Following Teleconference With the FDA
March 24, 2010
BioRelix and Dalton Medicinal
Chemistry Expand and Renew Research Agreement to Capitalize on Riboswitches
March 23, 2010
Oxford Immunotec announces contract
with Scancell Ltd to measure T cell
March 23, 2010
Transcept Pharmaceuticals Granted Second U.S. Patent Covering Intermezzo® Formulation
March 23, 2010
WorldHeart Announces Levacor VAD Implant at
the University of Utah
March 23, 2010
Prometheus and Bayer Schering Pharma to Apply
Novel Diagnostic Platform to Oncology Therapeutic Candidates
March 17, 2010
Affymax® Receives $5 Million Milestone Payment
on Initiation of Phase 3 Clinical Trials for Hematide™ in Japan
March 10, 2010
ISTA Pharmaceuticals Receives Action Date for
FDA Review of Once-Daily XiDay™
March 8, 2010
Auxilium Announces Availability of
XIAFLEX™ for the Treatment of Dupuytren's Contracture
March 8, 2010
NxStage Announces New FREEDOM Data
Showing the Positive Impact of its Daily Home Hemodialysis Therapy on Sleep
Quality and Restless Legs Syndrome
March 8, 2010
ReShape Medical Announces Initiation of U.S.
Clinical Study for Weight Loss
March 3, 2010
NxStage® and Dirinco Sign Distribution Agreement For System
One™ in the Netherlands
March 2, 2010
Tioga Pharmaceuticals, Inc. Raises $18 Million
to Fund Phase 3 Clinical Trial in Irritable Bowel Syndrome
February 17, 2010
Transcept Pharmaceuticals Granted First U.S.
Patent Covering Intermezzo® Formulation
February 9, 2010
Auxilium Announces U.S. Food and Drug
Administration Approval for XIAFLEX™ for the Treatment of Dupuytren's
Contracture
February 3, 2010
NxStage® and Nordic Medcom Sign
Distribution Agreement for the System One™
February 3, 2010
Pearl Therapeutics Raises $15 Million to
Advance PT003, LAMA/LABA Combination Bronchodilator for COPD, into Phase 2b
Study
February 1, 2010
World Heart Corp. Completes $7.3 Million Private Placement
January 26, 2010
Prometheus Acquires Exclusive Rights to
PROLEUKIN® (aldesleukin) in the U.S.
January 26, 2010
Labcyte Expands Acoustic Dispensing
and Launches Into New Markets
January 26, 2010
Affymax Completes Treatment and Last
Patient Follow-up in Phase 3 Program for Investigational Drug,
Hematide™, to Treat Anemia in Chronic Renal Failure
January 25, 2010
Pfizer and Auxilium Announce Commencement of
European Regulatory Review of XIAFLEXTM for the Treatment of Dupuytren's
Contracture
January 21, 2010
WorldHeart Announces First U.S. Implant of
Levacor™ VAD Implant at INTEGRIS in Oklahoma City
January 19, 2010
ISTA Pharmaceuticals announces trial results
for topical Xibrom 0.09%
January 11, 2010
WorldHeart Receives Unconditional BTT Study
Approval From FDA for Levacor™ VAD
January 8, 2010
Tolerx Completes Enrollment in
DEFEND-1, a Phase 3 Type 1 Diabetes Study with Otelixizumab
January 7, 2010
Sopherion Therapeutics Receives FDA
Fast Track Designation for Myocet in Metastatic Breast Cancer
January 7, 2010
Prometheus Completes $260 Million Financing
January 7, 2010
Pearl Therapeutics Announces Positive Results
from Phase 2a Trial of Glycopyrrolate Inhalation Aerosol in Chronic Obstructive
Pulmonary Disease
January 6, 2010
Pearl Therapeutics Announces Positive Results
from Phase 2a Trial of Formoterol Inhalation Aerosol in Chronic Obstructive
Pulmonary Disease
January 4, 2010
Newly Formed Durata Therapeutics Acquires
Pfizer’s Vicuron Subsidiary
December 21, 2009
ISTA Pharmaceuticals Submits Supplemental New
Drug Application to the FDA for Once-Daily XiDay™
December 17, 2009
Auxilium Announces Top Line Phase IIb
XIAFLEX™ Peyronie's Results
December 16, 2009
Roche Licenses First-in-Class Treatments for
Chronic Pain to Afferent Pharmaceuticals; Afferent Secures $23 Million in Series
A Financing
December 16, 2009
Transcept Pharmaceuticals Receives Notice of
Allowance for Second U.S. Patent Application Covering Intermezzo®
December 14, 2009
WuXi PharmaTech Selects Labcyte POD™ 810
Platform for High-Throughput Screening
December 07, 2009
Affymax Announces Close of Common Stock
Offering and Exercise of Underwriters' Overallotment Option
November 24, 2009
WorldHeart Signs Agreements for
Next-Generation Minimally Invasive Blood Pump
November 17, 2009
NeuroStar TMS Therapy® Receives Prestigious
Popular Science Award
November 12, 2009
3M Licenses Vaccine Adjuvants to VaxInnate
November 9, 2009
Concert Pharmaceuticals Initiates Phase 1b
Clinical Trial of CTP-518, Protease Inhibitor for Treatment of HIV
November 9, 2009
Transcept Pharmaceuticals Receives Notice of
Allowance for U.S. Patent Application on Intermezzo®
November 4, 2009
Affymax and Takeda Announce Preliminary Phase 2 Data Demonstrated That
Hematide™ Increased Hemoglobin in Dialysis Patients
October 30, 2009
Epocrates Celebrates 10 Years of Innovation
October 29, 2009
FDA Clears Interlace Medical’s MyoSure™
Hysteroscopic Tissue Removal System for The Treatment of Submucosal Fibroids
October 28th, 2009
Ligand to Acquire Metabasis for Cash and Contingent Value Rights
October 27, 2009
NxStage® Reports Significant Interim FREEDOM Study Results
October 27, 2009
Synageva Biopharma Announces
Completion of $45 Million Financing with New $12 Million Investment, Addition of
New Leaf Venture Partners to Investor Group, and Expansion of Senior Leadership
Team
October 20, 2009
Prometheus Awarded Patent Related to Genetic
Testing for Inflammatory Bowel Disease
October 20, 2009
WorldHeart Receives IRB Approval at First Center in the Levacor™ VAD BTT Clinical Trial Center On-Site Training Completed
October 15, 2009
Prometheus Launches ProOncDx Cancer Diagnostics
October 15, 2009
Relypsa Initiates Phase 2b Clinical Trial of
RLY5016 for the Prevention of Hyperkalemia in Heart Failure Patients
October 7, 2009
Direct Flow Medical Presents Twelve Month
Clinical Results with their Percutaneous Aortic Valve System at TCT
October 5, 2009
Boston Business Journal Names NxStage® Medical
Third Fastest Growing Company in Massachusetts
October 1, 2009
Cyberonics Announces Epilepsy Technology
Collaborations
October 1, 2009
Labcyte Signs Bioscreen Instruments as
Exclusive Distributor in India
September 23, 2009
Intarcia Therapeutics, Inc. Commences
Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes
September 17, 2009
U.S. Food and Drug Administration's Arthritis
Advisory Committee Votes Unanimously 12-0 to Recommend Approval of XIAFLEX™ for
Dupuytren's Contracture
September 16, 2009
Concert Pharmaceuticals Presents
Clinical Results Demonstrating Reduced Drug-Drug Interactions with a
Deuterium-Modified Compound
September 14, 2009
NxStage® Announces Streamline® Blood Tubing
Set Supply Agreement Between Medisystems® and Reliant Renal Care
September 14, 2009
Affymax Provides Phase 3 Program
Update for Investigational Drug, Hematide™, to Treat Anemia in Chronic Renal
Failure
September 9, 2009
Prometheus Announces Co-Pay Assistance Savings
Program For LOTRONEX® (Alosteron Hcl) Tablets
September 9, 2009
ISTA Pharmaceuticals' Bepreve™
Receives FDA Approval for the Treatment of Ocular Itching Due to
Allergies
September 8, 2009
ISTA Pharmaceuticals Announces Preliminary
Results of T-Pred Studies
September 8, 2009
XIAFLEX™ CORD I Study Published in New
England Journal of Medicine
September 2, 2009
Abbott to Acquire Visiogen, Expanding Vision Care Portfolio
September 2, 2009
New Leaf Venture Partners Leads $30 Million Financing in Neuronetics
September 2, 2009
Tioga Pharmaceuticals, Inc. and Ono
Pharmaceutical Co. Announce Agreement to Develop and Commercialize Asimadoline
in Japan
September 1, 2009
Aureon Laboratories Announces Appointment of
New CEO
August 25, 2009
ISTA Pharmaceuticals Announces Positive
Preliminary Phase 3 Clinical Results to Support sNDA Filing for
Once-Daily Xibrom™ 0.09%
August 25, 2009
WorldHeart Receives US Clinical Study Approval for the Levacor™ VAD
August 20, 2009
Labcyte Awarded Second Japanese Patent
August 18, 2009
XDx Completes $14.4 Million Series G
Financing XDx Poised to Achieve Break-Even in 2010
August 5, 2009
Auxilium Pharmaceuticals, Inc. Secures $30
Million Revolving Credit Line With Silicon Valley Bank
August 5, 2009
Dr. Nathaniel Brown Joins Presidio
Pharmaceuticals, Inc. as Senior Vice President of Clinical
Development
August 5, 2009
Purdue Pharmaceutical Products L.P. and
Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to
Commercialize Intermezzo® in the United States
August 2, 2009
U.S. Food and Drug Administration's
Arthritis Advisory Committee Confirms Date to Review XIAFLEX™
for the Treatment of Dupuytren's Contracture
July 31, 2009
Affymax Announces Data Monitoring Committee
Review of Phase 3 Hematide Program
July 20, 2009
Presidio Pharmaceuticals Inc. Raises $27 Million in Additional Financing
July 9, 2009
Presidio Pharmaceuticals, Inc. selects PPI-461 as a Clinical Candidate in their Hepatitis C Virus NS5A Program
July 7, 2009
Prometheus Launches MyCeliacID™, The First Do It Yourself, Saliva-Based Genetic Test Dedicated To Celiac Disease
June 29, 2009
U.S. Food and Drug Administration's Arthritis
Advisory Committee Sets Tentative Date to Review XIAFLEX™
for the Treatment of Dupuytren's Contracture
June 18, 2009
Transcept Pharmaceuticals Announces
Expected FDA Extension of Regulatory Review Period for
Intermezzo®
June 11, 2009
Metabasis Therapeutics
Announces That Its Collaborator Merck & Co., Inc. Has
Selected a Lead AMPK Activator for Late Preclinical
Development and Has Agreed to Make a One-Time Payment for
All Remaining Financial Obligations
June 10, 2009
Metabasis Therapeutics
Receives a Development Event Payment from Roche and
Notification That Roche Plans to Advance MB11362 into
Development for the Treatment of Hepatitis C
June 5, 2009
Concert
Pharmaceuticals and GlaxoSmithKline Form Alliance to Develop
Novel Deuterium Modified Drugs
June 2, 2009
Prometheus Announces New
Findings Regarding Patients at Risk for Celiac Disease at
DDW
June 2, 2009
NxStage Extends Supply
Agreement with B. Braun Medical Inc. to Include
Streamline(R) Technology
June 1, 2009
Affymax® Reports Phase 2 Clinical
Trial Data Supporting Hemoglobin Increases with Once-Per-Month Hematide™ Regardless of Patient
Baseline Renal Function
May 26, 2009
Transcept Pharmaceuticals
Presents Data from Studies of Two Product Candidates at
Annual Meeting of the American Psychiatric Association
May 21, 2009
NxStage Announces
Strategic Business Alliance with Asahi Kasei Kuraray Medical
May 18, 2009
VaxInnate Corporation
Closes $30 Million Round of Financing; Wellcome Trust Leads
Round
May 6, 2009
XIAFLEX™ for the
Treatment of Dupuytren's Contracture Receives Priority Review
from the U.S. Food and Drug Administration
April 28, 2009
Prometheus and
Rosetta Genomics Announce License and Collaboration
Agreement
April 13, 2009
Prometheus
Highlights Record Performance in 2008
March 24, 2009
NxStage
Announces Credit Facility Amendment
March 16, 2009
Prometheus
Receives New York State Approval for Prometheus® IBS
Diagnostic, First Blood Test for Irritable Bowel Syndrome
March 16, 2009
Auxilium Submits
Biologics License Application for XIAFLEX™ for the Treatment of Dupuytren's Contracture to the U.S. Food and Drug
Administration
March 02, 2009
IlluminOss Medical Receives ISO 13485 Certification
February 20, 2009
IlluminOss
Announces First Human Case Utilizing Its Innovative
Photodynamic Bone Stabilization System Technology
February 19, 2009
Affymax Announces
$42 Million Private Placement
February 17, 2009
Auxilium Pharmaceuticals, Inc. Completes
Enrollment in Phase IIb Clinical Trial of XIAFLEX™
in Peyronie's Disease
February 2, 2009
Novacea Stockholders Approve Merger With Transcept
January 27, 2009
ISTA
Pharmaceuticals Announces Positive Results for Phase IIb
Study of Ecabet Sodium
January 22, 2009
WorldHeart Submits IDE Application for a
Pivotal Bridge-to-Transplant Study of the Levacor™ VAD
January 8, 2009
|
